Molecular mechanisms of idiopathic pulmonary fibrosis: Emerging therapeutic approaches

https://doi.org/10.56238/sevened2023.007-033

Victoria Souza Araujo
Nursing student
School of Health Sciences - ESCS
E-mail: victoriax.araujo@gmail.com

Andréa Maria de Paula Siqueira
Graduated in Nursing
University of Fortaleza - UNIFOR
Graduate Nurse
E-mail: andrea.mps@hotmail.com

Carlos Santos Teixeira
Graduated in Nursing
University of Fortaleza - UNIFOR, Currently working at Hospital do Coração and Hospital Geral de Fortaleza
E-mail: carlosteixeira20@gmail.com

Edilma Casimiro Gomes Serafim
Nurse, Master in Public Health
University of Fortaleza
E-mail: edilmacasimiro@yahoo.com.br

Élida Maria Silva Gregório
Medical student
Estácio University Center of Ribeirão Preto.
E-mail: elidagregorio143@gmail.com

Ihury Garofo Kennedy Anunciação de Mello
Graduated in Medicine
Estácio University Center of Ribeirão Preto.
E-mail: garofo_ihury@hotmail.com

Ithalo Garofo Kennedy Anunciação de Mello
Graduated in Medicine
Estácio University Center of Ribeirão Preto.
E-mail: ithalogarofo@hotmail.com

Jadson Soares Laudelino
Graduated in Medicine, Resident in Pulmonology
State University of Health Sciences of Alagoas - Uncisal
E-mail: jadsonlaudelino@gmail.com

Safira Monteiro Costa
Medical student
University of Rio Verde
E-mail: safiramonteiro.c@gmail.com

Silvia Helena Varela Mororó
Graduated in Nursing
Federal University of Ceará, working at Dr. Carlos Alberto Studart Gomes Hospital
E-mail: silviamororo@hotmail.com

ABSTRACT
Idiopathic Pulmonary Fibrosis (IPF) stands as one of the most puzzling interstitial lung diseases within respiratory medicine, marked by a relentless progression that impairs lung function. Despite its elusive etiology, recent breakthroughs in molecular biology and genomics have granted a deeper understanding of the intricate cellular and molecular pathways implicated in its pathogenesis. This paper seeks to provide a comprehensive and up-to-date insight into these molecular mechanisms, emphasizing their significance in the development of novel therapeutic approaches and intervention strategies aimed at curbing the disease's progression and enhancing the life quality of affected patients..

Keywords: Idiopathic Pulmonary Fibrosis, Molecular Pathogenesis, Emerging Therapies, Molecular Biology, Genomics.

1 INTRODUCTION

Idiopathic Pulmonary Fibrosis (IPF) emerges as one of the most enigmatic pathologies in the scenario of lung diseases, standing out for its chronic, progressive and often fatal nature. This condition, whose etiology is still mysterious, presents itself as a dilemma in the field of respiratory

medicine, as its clinical behavior is often unpredictable, making patient management a constant challenge for health professionals (Raghu et al., 2015).

In the scientific field, IPF has also been the center of numerous investigations, given its multifaceted and intricate pathophysiology. The course of the disease is marked by an accumulation of fibrosis in the lungs, leading to a progressive deterioration of lung function and significantly compromising the quality of life of patients (Selman et al., 2001).

The quest to understand the molecular complexity of IPF has been one of the pillars of contemporary research. The need to unravel the pathogenic mechanisms behind pulmonary fibrosis has led to an ongoing race for innovative therapeutic approaches that may offer better prospects for treatment, prognosis, and eventually a cure for this unnerving condition (Raghu et al., 2015).

In a scenario where therapeutic options for IPF are limited and often only palliative, deepening the molecular and cellular understanding of this disease is more than an academic necessity: it is a clinical urgency. With this review, we propose a journey through the molecular universe of IPF, aiming to contribute to the existing literature and hopefully pave the way for further advances in the treatment of this condition.

2 METHODOLOGY

The present study was structured in the form of a systematic review, a rigorous and standardized approach that aims to minimize biases and provide a broad and detailed view of a specific topic, thus ensuring the reliability and validity of the information presented.

For data collection, we chose to consult the main internationally recognized scientific databases: PubMed, a comprehensive repository of biomedical literature; ScienceDirect, which covers a wide range of scientific disciplines; and Web of Science, known for its wide coverage of journals from various areas of science.

Regarding the type of publication, the selection of clinical trials was prioritized, given their relevance in providing robust evidence on the efficacy and safety of therapeutic approaches. Systematic reviews and meta-analyses were also considered, due to their ability to synthesize large volumes of information and provide conclusions based on a broad set of studies.

All articles were submitted to a critical evaluation, examining the methodological quality, the relevance to the proposed theme, and the relevance of the conclusions presented. Thus, we sought to compile an informative and reliable synthesis about the molecular mechanisms of Idiopathic Pulmonary Fibrosis and the emerging therapeutic approaches.

3 LITERATURE REVIEW

3.1 MOLECULAR MECHANISMS:

One of the most studied pathways in the context of pulmonary fibrosis is the Transforming Growth Factor-beta (TGF-β) pathway. This growth factor is widely recognized for its ability to induce the differentiation of fibroblasts into myofibroblasts. The latter, characterized by smooth muscle alpha-actin expression, have a robust ability to produce and secrete extracellular matrix components, especially collagen, culminating in an abnormal accumulation of matrix in the lung interstitial spaces (Wynn, 2011). In addition, studies show that persistent activation of the TGF-β pathway can promote resistance to apoptosis in myofibroblasts, further consolidating its presence in fibrous tissue (Duffield et al., 2013).

Type II pneumocytes, specialized epithelial cells, perform a number of vital functions, including the synthesis and secretion of pulmonary surfactant and serving as progenitors for type I pneumocytes. This, in turn, potentiates the progression of fibrosis (Selman et al., 2001). Recent research also emphasizes the role of type II pneumocytes in triggering immune responses that favor fibrosis (Herazo-Maya et al., 2013).

Matrix metalloproteinases (MMPs) are enzymes that play critical roles in extracellular matrix remodeling. In IPF, there is an imbalance between MMPs and their inhibitors, the metalloproteinase-inhibiting tissues (TIMPs). This imbalance favors an excessive accumulation of matrix, feeding the fibrosing process (King et al., 2011).

3.2 EMERGING THERAPEUTIC APPROACHES:

The search for effective therapies for IPF has been intense and challenging. Pirfenidone and nintedanib have emerged as the main therapeutic options that have demonstrated efficacy in phase III clinical trials. Both agents were able to significantly reduce the decline in lung function, as measured by forced vital capacity, in patients with IPF (Richeldi et al., 2014).

Wnt/β-catenin signaling is abnormally active in IPF. This pathway regulates several cellular functions, including proliferation, differentiation, and survival. Therefore, modulation of this pathway represents a promising therapeutic strategy. Several inhibitors of this pathway are currently under investigation in preclinical models, and some have shown potential in attenuating fibrosis progression (Konigshoff et al., 2010).

4 DISCUSSION

Idiopathic Pulmonary Fibrosis (IPF) remains one of the biggest enigmas in the field of interstitial lung diseases. Over the past few decades, many advances have been made in understanding the molecular mechanisms underlying IPF. These advances have not only shed light on some of the complex molecular pathways involved, but have also provided the identification of potential

therapeutic targets that can be explored in search of a cure or, at least, an effective treatment that can improve patients' quality of life and slow the progression of the disease.

A crucial point that emerges from this understanding is the intricate signaling network that coordinates lung homeostasis. Imbalance in any of these mechanisms, whether due to damage to type II pneumocytes, activation of the TGF-β pathway, or disturbances in the balance of metalloproteinases, can trigger a cascade of events that culminate in pulmonary fibrosis (Raghu et al., 2015). This interconnected network suggests that multi-point intervention may be necessary for truly effective therapy.

In view of the multifactorial nature of IPF, monotherapies, while promising, may not be sufficiently comprehensive. The combination of therapeutic approaches that act on different molecular pathways of the disease could potentiate the beneficial effects, attenuating the progression of the disease from different fronts. This combination of therapies could be the key to overcoming the limitations seen with currently available treatments, which often provide only temporary or partial relief for patients (Selman et al., 2001).

In addition, it is worth noting that individualization of treatment, taking into account the molecular and genetic characteristics of each patient, can play a vital role in the development of more effective therapeutic strategies in the future. Such personalized approaches could improve the efficacy of treatments and reduce potential side effects, maximizing benefits for patients (Herazo-Maya et al., 2013).

In conclusion, the growing understanding of the molecular mechanisms of IPF not only illuminates the complexity of this condition but also opens doors for innovative therapeutic approaches. The combination of therapies, grounded in a solid understanding of the underlying mechanisms of the disease, emerges as a promising proposal to address the challenges of IPF.

5 CONCLUSION

Idiopathic Pulmonary Fibrosis (IPF) has been the subject of intensive study and investigation over the past few decades, reflecting the critical need to understand its complex etiology and develop effective treatments. As we unravel more about the intricate network of molecular mechanisms that contribute to IPF, it becomes evident that a one-size-fits-all approach is unlikely to be enough to treat this multifaceted condition.

Therapies such as pirfenidone and nintedanib undoubtedly represent a milestone in the treatment of IPF, offering hope and an improvement in quality of life for many patients. However, they also serve as a reminder that while we have made significant progress, there is still a long way to go. The ongoing challenge is to develop therapies that not only alleviate symptoms, but that can, in fact, slow or even reverse the progression of the disease.

To achieve this goal, interdisciplinary collaboration between clinicians, molecular biologists, geneticists, and pharmacologists will be essential. With the advancement of biotechnology and genomic sciences, personalized medicine could also play a crucial role, allowing for more targeted interventions based on the genetic and molecular characteristics of each patient.

Ultimately, the search for more effective treatments for IPF, anchored in a deep molecular understanding, is not just an academic aspiration, but an imperative necessity to improve the lives of countless patients affected by this devastating disease.

REFERENCES

DUFFIELD, J. S. et al. Host Responses in Tissue Repair and Fibrosis. Annual Review of Pathology: Mechanisms of Disease, v. 8, n. 1, p. 241–276, 24 jan. 2013.

HERAZO-MAYA, J. D. et al. Peripheral Blood Mononuclear Cell Gene Expression Profiles Predict Poor Outcome in Idiopathic Pulmonary Fibrosis. Science Translational Medicine, v. 5, n. 205, 2 out. 2013.

KING, T. E.; PARDO, A.; SELMAN, M. Idiopathic pulmonary fibrosis. The Lancet, v. 378, n. 9807, p. 1949–1961, dez. 2011.

KÖNIGSHOFF, M.; EICKELBERG, O. WNT Signaling in Lung Disease. American Journal of Respiratory Cell and Molecular Biology, v. 42, n. 1, p. 21–31, jan. 2010.

RAGHU, G. et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, v. 192, n. 2, p. e3–e19, 15 jul. 2015.

RICHELDI, L. et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, v. 370, n. 22, p. 2071–2082, 29 maio 2014.

SELMAN, M.; KING, T. E.; PARDO, A. Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy. Annals of Internal Medicine, v. 134, n. 2, p. 136, 16 jan. 2001.

WYNN, T. A. Integrating mechanisms of pulmonary fibrosis. The Journal of Experimental Medicine, v. 208, n. 7, p. 1339–1350, 4 jul. 2011.